<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004205</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067451</org_study_id>
    <secondary_id>IBCSG-18-98</secondary_id>
    <secondary_id>DAN-DBCG-IBCSG-1-98</secondary_id>
    <secondary_id>FRE-FNCLCC-IBCSG-1-98</secondary_id>
    <secondary_id>EU-99022</secondary_id>
    <secondary_id>NOVARTIS-2026703019</secondary_id>
    <secondary_id>BIG-1-98</secondary_id>
    <nct_id>NCT00004205</nct_id>
  </id_info>
  <brief_title>Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer</brief_title>
  <acronym>BIG 1-98</acronym>
  <official_title>A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
      letrozole may fight breast cancer by reducing the production of estrogen. Hormone therapy
      using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor
      cells. If is not yet known which treatment regimen is most effective for breast cancer.

      PURPOSE: Randomized double-blind phase III trial to compare the effectiveness of letrozole
      with that of tamoxifen in treating postmenopausal women who have breast cancer that has been
      surgically removed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare adjuvant letrozole vs tamoxifen administered for 5 years in postmenopausal women
           with operable, hormone receptor-positive breast cancer.

        -  Compare these treatment regimens given sequentially vs continuously in this patient
           population.

        -  Compare these treatment regimens in terms of overall survival, disease-free and
           systemic-free survival, safety, and tolerability in this patient population.

      OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified
      according to adjuvant chemotherapy (prior therapy vs no prior or concurrent therapy vs
      concurrent therapy), prior surgery (modified radical mastectomy vs a lesser surgical
      procedure), and participating center. Patients are randomized to one of four treatment arms.

        -  Arm I: Patients receive adjuvant oral tamoxifen daily for 5 years.

        -  Arm II: Patients receive adjuvant oral letrozole daily for 5 years.

        -  Arm III: Patients receive adjuvant oral tamoxifen daily for 2 years followed by adjuvant
           oral letrozole daily for 3 years.

        -  Arm IV: Patients receive adjuvant oral letrozole daily for 2 years followed by adjuvant
           oral tamoxifen daily for 3 years.

      Patients may receive concurrent radiotherapy. Some patients receive concurrent adjuvant
      chemotherapy beginning within 8 weeks after surgery and continuing for no more than 6 months.

      Patients are followed annually.

      PROJECTED ACCRUAL: A total of 5,180 patients (1,295 per treatment arm) will be accrued for
      this study within 6 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <completion_date type="Actual">June 30, 2016</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival.</measure>
    <time_frame>Up to end of year 2015</time_frame>
    <description>Time from randomization to recurrence (including recurrence restricted to the breast after breast conserving treatment), metastasis, appearance of a second primary tumor, or death from any cause, whichever occurs first, assessed up to end of year 2015, for a maximum of 17 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to end of year 2015</time_frame>
    <description>Time from randomization to death from any cause, assessed up to end of year 2015, for a maximum of 17 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>5 years after randomization.</time_frame>
    <description>Morbidity information will be recorded using the Adverse Event Form (AE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic relapse</measure>
    <time_frame>Up to end of year 2015</time_frame>
    <description>Time from randomization to appearance of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation, or the contralateral breast, assessed up to end of year 2015, for a maximum of 17 years</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">8028</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen for 5 years after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole for 5 years after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen, then letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen for 2 years after randomization, then letrozole for the next 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole, then tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole for 2 years after randomization, then tamoxifen for the next 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Letrozole 2.5 mg daily oral administration.</description>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_label>Tamoxifen, then letrozole</arm_group_label>
    <arm_group_label>Letrozole, then tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Tamoxifen 20 mg daily oral administration.</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_label>Tamoxifen, then letrozole</arm_group_label>
    <arm_group_label>Letrozole, then tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed resectable adenocarcinoma of the breast

               -  pT1, pT2, pT3, or minimal dermal involvement on pathology only

               -  pN0, pN1, pN2, or M0

                    -  Negative nodal status

                         -  At least 8 nodes are negative

                    -  Unknown nodal status

                         -  Less than 8 nodes examined and no pathological finding

                    -  Positive nodal status

                         -  Any positive finding independent of the number of nodes examined

               -  Negative sentinel node or no prior nodal dissection allowed if all other criteria
                  met

          -  Must have had total mastectomy, lumpectomy, or quadrantectomy

               -  Should have prior chest wall radiotherapy after segmental mastectomy or
                  histopathologic T4 dermal involvement

          -  Stage I, II, or IIIa allowed if the tumor is completely removed macroscopically and
             margins of the resected tumor are microscopically free of tumor

          -  Must undergo chest wall radiotherapy or second resection if microscopic disease at the
             mastectomy margins

          -  No bilateral disease except in situ disease, either ductal or lobular of the
             contralateral breast

          -  Postmenopausal

               -  Regardless of prior hormonal replacement therapy (HRT) or hysterectomy:

                    -  Bilateral oophorectomy and any age

                    -  Radiologic castration and amenorrheic for at least 3 months and any age

                    -  Not postmenopausal at the start of adjuvant chemotherapy AND and completed
                       at least 6 courses of prior cyclophosphamide, methotrexate, and fluorouracil
                       (CMF) or at least 4 courses of prior anthracycline-cyclophosphamide
                       continuation therapy and at least age 45 with follicle stimulating hormone
                       (FSH), luteinizing hormone (LH), and estradiol (E2) postmenopausal levels

               -  No prior HRT:

                    -  Prior hysterectomy and less than age 55 with FSH/LH/E2 postmenopausal levels

                    -  Prior hysterectomy and at least age 55

               -  No prior HRT or hysterectomy:

                    -  Amenorrhea more than 1 year and less than age 50

                    -  Amenorrhea more than 6 months and at least age 50

               -  Prior HRT regardless of hysterectomy:

                    -  At least 1 month since prior HRT and less than age 55 with FSH/LH/E2
                       postmenopausal levels

                    -  At least 1 month since prior HRT and at least age 55

               -  FSH/LH/E2 postmenopausal levels and uncategorized

          -  No distant metastases, including bone scans showing hot spots unconfirmed as benign
             disease or skeletal pain of unknown cause

          -  At least 10% hormone receptor-positive tumor cells

          -  Hormone receptor status:

               -  Estrogen receptor positive AND/OR

               -  Progesterone receptor positive

        PATIENT CHARACTERISTICS:

        Age:

          -  30 and over

        Sex:

          -  Female

        Menopausal status:

          -  Postmenopausal

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC greater than 3,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin greater than 10 g/dL

        Hepatic:

          -  Bilirubin less than 3.0 mg/dL

          -  SGOT or SGPT less than 1.5 times upper limit of normal

          -  No hepatic disease that would preclude study

        Renal:

          -  Creatinine less than 1.8 mg/dL

          -  No renal disease that would preclude study

        Cardiovascular:

          -  No cardiovascular disease that would preclude study

          -  Prior deep vein thrombosis allowed if medically stable

        Pulmonary:

          -  No lung embolism

        Other:

          -  No other prior or concurrent malignancy within the past 5 years except adequately
             treated basal or squamous cell skin cancer or carcinoma in situ of the cervix

          -  No prior noncompliance to medical regimens

          -  No other nonmalignant systemic diseases that would preclude follow-up

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Prior immunotherapy or biological response modifiers (e.g., interferon) allowed

        Chemotherapy:

          -  See Disease Characteristics

          -  Prior adjuvant or neoadjuvant chemotherapy allowed

          -  Concurrent adjuvant chemotherapy allowed

        Endocrine therapy:

          -  See Disease Characteristics

          -  Prior neoadjuvant hormonal therapy allowed (e.g., antiestrogens, progestins, or
             aromatase inhibitors) if no more than 4 months duration and no disease progression

          -  Prior corticosteroids allowed

          -  At least 4 weeks since prior HRT

          -  Prior adjuvant antiestrogen therapy allowed if less than 1 month duration and
             immediately after surgery, radiotherapy, and/or chemotherapy

          -  Prior antiestrogens for chemoprevention allowed if at least 18 months between
             completion of chemoprevention and diagnosis

          -  No other concurrent antiestrogens or aromatase inhibitors

          -  No concurrent raloxifene

          -  No concurrent systemic HRT with or without progestins of more than 3 months duration

        Radiotherapy:

          -  See Disease Characteristics

          -  Concurrent radiotherapy allowed

        Surgery:

          -  See Disease Characteristics

        Other:

          -  At least 30 days since prior systemic investigational drugs

          -  At least 7 days since prior topical investigational drugs

          -  Concurrent bisphosphonates allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beat Thurlimann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis Mauriac, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henning T. Mouridsen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Lipsitz M, Delea TE, Guo A. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. Curr Med Res Opin. 2010 Oct;26(10):2315-28. doi: 10.1185/03007995.2010.510784.</citation>
    <PMID>20731528</PMID>
  </reference>
  <reference>
    <citation>Skedgel C, Rayson D, Younis T, et al.: Direct and indirect economic evaluation of upfront and sequential adjuvant treatment in postmenopausal women with breast cancer based on the BIG 1-98 trial. [Abstract] J Clin Oncol 27 (Suppl 15): A-6594, 2009.</citation>
  </reference>
  <reference>
    <citation>Delea TE, El-Ouagari K, Karnon J, Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008 Apr;108(3):375-87. Epub 2007 Jul 26.</citation>
    <PMID>17653859</PMID>
  </reference>
  <reference>
    <citation>Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer. 2007 Jun;7(8):608-18.</citation>
    <PMID>17592673</PMID>
  </reference>
  <reference>
    <citation>Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin. 2006 Aug;22(8):1575-85. Review.</citation>
    <PMID>16870082</PMID>
  </reference>
  <reference>
    <citation>Scott LJ, Keam SJ. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer. Drugs. 2006;66(3):353-62. Review.</citation>
    <PMID>16526826</PMID>
  </reference>
  <reference>
    <citation>Wardley AM. Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. Clin Breast Cancer. 2006 Feb;6 Suppl 2:S45-50. Review.</citation>
    <PMID>16595026</PMID>
  </reference>
  <results_reference>
    <citation>Bouzyk M, Gray KP, Regan MM, et al.: ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer. [Abstract] J Clin Oncol 29 (Suppl 15): A-1002, 2011.</citation>
  </results_reference>
  <results_reference>
    <citation>Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011 Mar 20;29(9):1117-24. doi: 10.1200/JCO.2010.31.6455. Epub 2011 Feb 14.</citation>
    <PMID>21321298</PMID>
  </results_reference>
  <results_reference>
    <citation>De Censi A, Sun Z, Thurlimann BJK, et al.: Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence. [Abstract] J Clin Oncol 29 (Suppl 15): A-516, 2011.</citation>
  </results_reference>
  <results_reference>
    <citation>Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Müller S, Gelber RD, Price KN, Rasmussen BB, Viale G, Mouridsen H; Danish Breast Cancer Cooperative Group; BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol. 2012 May;23(5):1138-44. doi: 10.1093/annonc/mdr438. Epub 2011 Oct 10.</citation>
    <PMID>21986093</PMID>
  </results_reference>
  <results_reference>
    <citation>Huober JB, Cole BF, Wu J, et al.: Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial. [Abstract] J Clin Oncol 29 (Suppl 15): A-522, 2011.</citation>
  </results_reference>
  <results_reference>
    <citation>Phillips KA, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 2011 Feb;126(1):221-6. doi: 10.1007/s10549-010-1235-y. Epub 2010 Nov 3.</citation>
    <PMID>21046229</PMID>
  </results_reference>
  <results_reference>
    <citation>Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.</citation>
    <PMID>22018631</PMID>
  </results_reference>
  <results_reference>
    <citation>Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD; International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011 May 26;13(3):209. doi: 10.1186/bcr2837. Review.</citation>
    <PMID>21635709</PMID>
  </results_reference>
  <results_reference>
    <citation>Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol. 2011 Oct;22(10):2201-7. doi: 10.1093/annonc/mdq738. Epub 2011 Feb 18.</citation>
    <PMID>21335417</PMID>
  </results_reference>
  <results_reference>
    <citation>Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S; Swiss Group for Clinical Cancer Research (SAKK). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol. 2012 Jun;23(6):1474-81. doi: 10.1093/annonc/mdr448. Epub 2011 Oct 14.</citation>
    <PMID>22003243</PMID>
  </results_reference>
  <results_reference>
    <citation>Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A, Thürlimann B, Giobbie-Hurder A, Viale G, Altermatt HJ, Aebi S, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer. 2010 Feb 9;10:37. doi: 10.1186/1471-2407-10-37.</citation>
    <PMID>20144231</PMID>
  </results_reference>
  <results_reference>
    <citation>Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast. 2010 Oct;19(5):388-95. doi: 10.1016/j.breast.2010.03.025. Epub 2010 Apr 10.</citation>
    <PMID>20385495</PMID>
  </results_reference>
  <results_reference>
    <citation>Ribi K, Aldridge J, Phillips K, et al.: Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. [Abstract] J Clin Oncol 28 (Suppl 15): A-527, 2010.</citation>
  </results_reference>
  <results_reference>
    <citation>BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.</citation>
    <PMID>19692688</PMID>
  </results_reference>
  <results_reference>
    <citation>Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.</citation>
    <PMID>19528136</PMID>
  </results_reference>
  <results_reference>
    <citation>Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.</citation>
    <PMID>19474112</PMID>
  </results_reference>
  <results_reference>
    <citation>Regan MM, Colleoni M M, Giobbie-Hurder A, et al.: Adjusting for selective crossover in analyses of letrozole (Let) versus tamoxifen (Tam) in the BIG 1-98 trial. [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-16, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Ribi KE, Phillips KA, Sun Z, et al.: Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. [Abstract] J Clin Oncol 27 (Suppl 15): A-510, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Sun Z, Goldhirsch A, Price KN, Colleoni M, Ravaioli A, Simoncini E, Campbell I, Gelber RD, Towler M. Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer. Breast. 2009 Apr;18(2):84-8. doi: 10.1016/j.breast.2009.01.003. Epub 2009 Feb 24.</citation>
    <PMID>19243946</PMID>
  </results_reference>
  <results_reference>
    <citation>Viale G, Regan MM, Dell'Orto P, et al.: Central review of ER, PgR and HER2 in BIG 1-98 evaluating letrozole vs. letrozole followed by tamoxifen vs. tamoxifen followed by letrozole as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-76, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Zaman K, Thürlimann B, Huober J, et al.: Modelling bone mineral density in Swiss breast cancer patients treated with letrozole, tamoxifen and sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-5037, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008 Apr 20;26(12):1972-9. doi: 10.1200/JCO.2007.14.0459. Epub 2008 Mar 10.</citation>
    <PMID>18332471</PMID>
  </results_reference>
  <results_reference>
    <citation>Doughty JC. A review of the BIG results: the Breast International Group 1-98 trial analyses. Breast. 2008 Jan;17 Suppl 1:S9-S14. doi: 10.1016/S0960-9776(08)70003-1. Review.</citation>
    <PMID>18279765</PMID>
  </results_reference>
  <results_reference>
    <citation>Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al.: BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-13, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20.</citation>
    <PMID>18083065</PMID>
  </results_reference>
  <results_reference>
    <citation>Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.</citation>
    <PMID>18981464</PMID>
  </results_reference>
  <results_reference>
    <citation>Wardley AM. Understanding the BIG results: Insights from the BIG 1-98 trial analyses. Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Review.</citation>
    <PMID>19096768</PMID>
  </results_reference>
  <results_reference>
    <citation>Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2.</citation>
    <PMID>17200148</PMID>
  </results_reference>
  <results_reference>
    <citation>Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, Thürlimann B, Mauriac L, Forbes JF, Paridaens R, Gelber RD, Colleoni M, Smith I, Price KN, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007 Dec 20;25(36):5715-22. Epub 2007 Nov 12.</citation>
    <PMID>17998546</PMID>
  </results_reference>
  <results_reference>
    <citation>Crivellari D, Sun Z, Coates AS, et al.: Aromatase inhibitors (AI) for elderly patients: efficacy, compliance and safety according to patient age in the BIG 1-98 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-9033, 501s, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Koeberle D, Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat. 2007;105 Suppl 1:55-66. Epub 2007 Oct 3. Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):387.</citation>
    <PMID>17912636</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, Nogaret JM, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A; BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol. 2007 May;18(5):859-67. Epub 2007 Feb 14.</citation>
    <PMID>17301074</PMID>
  </results_reference>
  <results_reference>
    <citation>Monnier AM. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.</citation>
    <PMID>17492927</PMID>
  </results_reference>
  <results_reference>
    <citation>Rasmussen BB, Regan MM, Lykkesfeldt AE, et al.: Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. [Abstract] J Clin Oncol 25 (18 Suppl 20): A-538, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007 Sep 1;25(25):3846-52. Epub 2007 Aug 6.</citation>
    <PMID>17679725</PMID>
  </results_reference>
  <results_reference>
    <citation>Forbes JF. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Semin Oncol. 2006 Apr;33(2 Suppl 7):S2-7.</citation>
    <PMID>16730270</PMID>
  </results_reference>
  <results_reference>
    <citation>Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].</citation>
    <PMID>16382061</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>ductal breast carcinoma</keyword>
  <keyword>lobular breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

